Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 15/20 | 0.58 |
| ▸ | IL23R | Q5VWK5 | 2/20 | 0.56 |
| ▸ | GRPR | P30550 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29434537 | 0.97 | GLP1R (0.57) | GLP1RIL23RGRPR | |
| SCHEMBL30932143 | 0.95 | GLP1R (0.60) | GLP1R | |
| SCHEMBL30063985 | 0.95 | GLP1R (0.54) | GLP1RIL23RGRPR | |
| SCHEMBL30183034 | 0.95 | GLP1R (0.55) | GLP1RIL23RGRPR | |
| SCHEMBL29484310 | 0.94 | CTSL (0.53) | GLP1RIL23RGRPR | |
| SCHEMBL30063158 | 0.93 | GLP1R (0.57) | GLP1R | |
| SCHEMBL30932144 | 0.93 | GLP1R (0.59) | GLP1R | |
| SCHEMBL30208638 | 0.92 | GLP1R (0.57) | GLP1RIL23R | |
| SCHEMBL29489380 | 0.91 | CTSL (0.53) | GLP1RIL23RGRPR | |
| SCHEMBL29484311 | 0.91 | GLP1R (0.56) | GLP1RIL23RGRPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083851-A1 | POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2026-03-26 | — | — | US | disclosed |
| US-20250223280-A1 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2025-07-10 | — | — | US | disclosed |
| US-12312340-B2 | Potent ASGPR-binding compounds for the degradation of immunoglobulins and other proteins | AVILAR THERAPEUTICS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-12091402-B2 | Potent ASGPR-binding compounds for the degradation of immunoglobulins and other proteins | AVILAR THERAPEUTICS, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-20240279209-A1 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-08-22 | — | — | US | disclosed |
| US-20240101539-A1 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-03-28 | — | — | US | disclosed |
| WO-2022235699-A2 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12312340-B2 | Potent ASGPR-binding compounds for the degradation of immunoglobulins and other proteins | ASGR1, FCGR2A, FCGR3B | GLP1R 2456/4885IL23R 391/4885GRPR 534/4885 |
| US-20240279209-A1 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | ASGR1, FCGR2A, FCGR3B | GLP1R 2456/4885IL23R 391/4885GRPR 534/4885 |
| US-12091402-B2 | Potent ASGPR-binding compounds for the degradation of immunoglobulins and other proteins | ASGR1, FCGR2A, FCGR3B | GLP1R 2456/4885IL23R 391/4885GRPR 534/4885 |
| US-20250223280-A1 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | ASGR1, FCGR2A, FCGR3B | GLP1R 2456/4885IL23R 391/4885GRPR 534/4885 |
| US-20260083851-A1 | POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | ASGR1, FCGR2A, FCGR3B | GLP1R 1777/4885IL23R 175/4885GRPR 194/4885 |
| US-20240101539-A1 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | ASGR1, FCGR2A, FCGR3B | GLP1R 2456/4885IL23R 391/4885GRPR 534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.